首页/数据集/Additional file 1: of Investigating the landscape of US orphan product approvals

Additional file 1: of Investigating the landscape of US orphan product approvals

Figshare2018-10-23 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Additional_file_1_of_Investigating_the_landscape_of_US_orphan_product_approvals/7238645 数据链接链接失效反馈

官方服务：

资源简介：

Appendix: Approved Orphan Products Dataset. (XLSX 92Â kb)

应用场景：

创建时间：

2018-10-23

孤儿药审批

临床试验方法学

The aim of this study was to assess the correlation between the methodological characteristics of clinical trials on orphan drugs (ODs) and the registration status granted by the European Medicines Ag

Figshare2025-03-08 更新80

Table1_Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.XLSX

罕见病药物监管

真实世界数据应用

Background: Reference to so-called real-world data is more often made in marketing authorization applications for medicines intended to diagnose, prevent or treat rare diseases compared to more common

NIAID Data Ecosystem30

Number of products and grants approved by FDA as part of the Orphan Products Designation Program and the Orphan Products Grant Program, respectively.

孤儿药审批

罕见病药物

Number of products and grants approved by FDA as part of the Orphan Products Designation Program and the Orphan Products Grant Program, respectively.

NIAID Data Ecosystem10

Additional file 1: of Investigating the landscape of US orphan product approvals

孤儿药审批

罕见病治疗

Appendix: Approved Orphan Products Dataset. (XLSX 92Â kb)

Figshare2018-10-23 更新60

Number of products and grants approved by FDA as part of the Orphan Products Designation Program and the Orphan Products Grant Program, respectively.